Economics at your fingertips  

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Galin Michailov (), Glenn Davies and Karl Krobot

The European Journal of Health Economics, 2012, vol. 13, issue 3, 365-374

Keywords: Cost-effectiveness; Dyslipidaemia; Extended-release niacin; Hypercholesterolaemia; Laropiprant; Simvastatin; I10 (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations Track citations by RSS feed

Downloads: (external link) (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Series data maintained by Sonal Shukla ().

Page updated 2017-10-06
Handle: RePEc:spr:eujhec:v:13:y:2012:i:3:p:365-374